Intellectual Property

  The PTAB has become the frontline of IP battles, where patents are validated- or wiped out. Institution rates are climbing, with 74% of petitions advancing in FY 2024 , and nearly half of instituted claims invalidated. For innovators, that means defending your patents has never been harder.   Key 2025 shifts to watch:   Electrical/software dominance: These technologies account for nearly 7 in 10 petitions, and once challenged, about a quarter face complete invalidation.   Mechanical/EV under pressure: Over 20% of petitions, with invalidation rates around 27%.   Biopharma safer (for now): Only 6% of petitions, with final invalidation rates below 15%.   Rule changes create both risks and opportunities:   The Motion-to-Amend rule now offers real options to preserve patents with revised claims.   The restored Fintiv test makes early filing essential for challengers, while defenders must watch court schedules carefully.   The workload pi...

  Research institutes face tighter budgets, rising competition, and a flood of scientific publications and patent filings. The challenge? Turning promising ideas into market-ready innovations without losing speed or rigor. Here’s where AI-enabled IP platforms change the game: Semantic discovery: Find relevant prior art instantly—no missed patents hidden under different terminology. Auto-summaries: Reduce 100-page filings to concise briefs in seconds. Conversational analytics: Ask natural-language questions and get charts, claims, and evidence on demand. Visual search: Upload drawings or images to uncover look-alike patents and designs. Trend detection: Spot white spaces and choke points before rivals do. By embedding these tools early—from idea evaluation to licensing negotiations—research institutes can cut development cycles, boost patent quality, and focus resources on breakthroughs that matter most. 💡 Want to see how AI can accelerate...

  In high-investment industries like pharma and biotech, years can be lost waiting for regulatory approvals. The US Patent Term Extension (PTE) offers a lifeline—recovering that time and extending market exclusivity. Why it matters now: Recover lost years : Add up to 5 years to a patent term. Fair protection : Ensures at least 14 years of exclusivity post-approval. Life sciences edge : Covers drugs, biologics, and medical devices hit hardest by FDA review delays. Critical ROI : Every extra day of exclusivity can mean millions in revenue. Compared to PTA (delays during prosecution) or SPCs (Europe), PTE is uniquely tailored to regulatory hurdles in the US —making it an essential strategy for innovators navigating FDA timelines. 💡 Stay ahead in patent strategy—read the full blog to explore how PTE safeguards your IP investment. 👉 US Patent Term Adjustments - Extending Patent Life Through Strategic Prosecution - PatSeer